

41 - References

References

372 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 References

1. Horowitz MA, et al. Estimating risk of antidepressant withdrawal from a review of published data. *CNS Drugs* 2023; 37:143–157.
2. Horowitz MA, et al. Tapering of SSRI treatment to mitigate withdrawal symptoms. *Lancet Psychiatry* 2019; 6:538–546.
3. Cleare A, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. *J Psychopharmacol* 2015; 29:459–525.
4. Harvey BH, et al. New insights on the antidepressant discontinuation syndrome. *Hum Psychopharmacol* 2014; 29:503–516.
5. Malhi GS, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. *Aust N Z J Psychiatry* 2015; 49:1087–1206.
6. Benazzi F. Fluoxetine for the treatment of SSRI discontinuation syndrome. *Int J Neuropsychopharmacol* 2008; 11:725–726.
7. Perahia DG, et al. Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. *J Clin Psychiatry* 2008; 69:95–105.
8. Díaz-Tufinio CA, et al. Pharmacogenetic variants associated with fluoxetine pharmacokinetics from a bioequivalence study in healthy subjects. *Journal of Personalized Medicine* 2023; 13:1352.
9. el-Yazigi A, et al. Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. *J Clin Pharmacol* 1995; 35:17–21.
10. Horowitz M, et al. *The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs*. Oxford: Wiley-Blackwell; 2024.
11. Goodwin GM, et al. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry* 2009; 70:1128–1137.
12. Buckley NA, et al. Serotonin syndrome. *BMJ* 2014; 348:g1626.
13. Abadie D, et al. Serotonin syndrome: analysis of cases registered in the French pharmacovigilance database. *J Clin Psychopharmacol* 2015; 35:382–388.
14. Chen G, et al. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. *Clin Drug Investig* 2013; 33:727–736.

15. Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2014; 68:60-82.
-

Revision #1

Created 2026-01-04 20:15:28 UTC by Omar Ayman

Updated 2026-01-04 20:15:28 UTC by Omar Ayman